Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis - Matchaba, Patrice; Gitton, Xavier; Krammer, Gerhard; Ehrsam, Elena; Sloan, Victor Schorr; Olson, Melvin; Mellein, Bernhard; Hoexter, Godehard; Orloff, John; Garaud, Jean-Jacques (Clinical therapeutics, 2005)
Keywords: Anti-inflammatory agents; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Arthritis, Rheumatoid - drug therapy; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Cardiovascular disease; Cardiovascular Diseases - chemically induced; cardiovascular safety; Collaboration; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - therapeutic use; cyclooxygenase-2 inhibitor; Databases, Factual; Diclofenac - analogs & derivatives; Diseases of the osteoarticular system; Double-blind studies; Drug dosages; Drug therapy; Female; Heart attacks; Humans; Inflammatory joint diseases; Knee; Male; Medical sciences; meta-analysis; Middle Aged; Nonsteroidal anti-inflammatory drugs; NSAID; Organic Chemicals - adverse effects; Organic Chemicals - therapeutic use; Osteoarthritis; Osteoarthritis - drug therapy; Pharmacology; Pharmacology. Drug treatments; Randomized Controlled Trials as Topic - statistics & numerical data; Rheumatoid arthritis; Stroke; meta-analysis; cardiovascular safety; NSAID; osteoarthritis; cyclooxygenase-2 inhibitor; Prostaglandin-endoperoxide synthase; Toxicity; Diseases of the osteoarticular system; Autoimmune disease; Inflammatory joint disease; Cyclooxygenase 2 inhibitor; Metaanalysis; Clinical trial; Lumiracoxib; Degenerative disease; Safety; cyclooxygenase- 2 inhibitor; Human; Enzyme; Acute; Enzyme inhibitor; Non steroidal antiinflammatory agent; Chronic; Rheumatoid arthritis; Randomised controlled trial; Arthropathy; Oxidoreductases; Circulatory system; Osteoarthritis